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ABSTRACT
Myocardial infarction with ST segment elevation (STE) on electrocardiography (ECG) is a common presentation 
in emergency rooms across the world. Myocardial injury and necrosis are infrequently the initial presentation 
in patients with thrombotic thrombocytopenic purpura (TTP). A 48-year-old woman presented with STE 
myocardial infarction from outside hospital for primary percutaneous coronary intervention. However, her 
clinical picture was not consistent. Rapid evaluation revealed symptoms associated with microangiopathic 
hemolytic anemia, thrombocytopenia, acute kidney injury with waxing and waning mental status. A diagnosis 
of TTP was made with low ADAMST-13 activity. Plasmapheresis was initiated along with intravenous steroid 
therapy. The patient had a full recovery and went home after full recovery of left ventricular ejection fraction 
and normal myocardial perfusion studies. Rapid evaluation is needed to identify infrequent causes of STE 
myocardial infarction. As swift protocols are activated in the emergency room and catheterization laboratories 
to ensure quality control, it is equally important to integrate all aspects of the patient’s clinical and objective 
data to detect unusual disease entities.
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place that grade a hospital’s efficiency at caring for such 
patients.  [1] However, the time pressure to optimize such 
quality metrics may lead to an unintended rush to treatment 
prior to adequate evaluation.[1]
In this report, we present a rare case where myocardial 
infarction was seen as a presenting feature of an underlying 
hematologic disease, thrombotic thrombocytopenic 
purpura (TTP). This case highlights the importance of 
a thorough, yet efficient, clinical evaluation in which the 
history, physical exam, ECG and laboratory data were 
needed to make the appropriate triage decision and not 
miss an unusual diagnosis.
CASE REPORT
A 48-year-old woman with no known coronary risk 
factors was transferred from an outside facility to the 
cardiac catheterization laboratory of our hospital with 
Clinical Case Report Based Study
INTRODUCTION
Patients who present to the emergency department with 
chest pain require rapid triage, evaluation and management. 
Myocardial infarction with ST segment elevation (STE) 
on electrocardiography (ECG) is a common presentation 
in emergency rooms across the world. Acute coronary 
syndrome (ACS) marked by STE on the ECG warrants 
consideration for emergent cardiac catheterization and 
possible percutaneous coronary intervention (PCI). In 
fact, there are now core measures and quality metrics in 
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the diagnosis of STE myocardial infarction for primary 
PCI. On arrival to our catheterization laboratory, the ECG 
from the referring hospital showed sinus tachycardia with 
normal axis and intervals. There was STE in leads I, II, 
aVL, V4–6 and reciprocal ST segment depression in lead III 
[Figure 1]. Laboratory data were not yet available. However, 
the patient’s history of present illness was significant for 
malaise, fever, chills and lethargy that began 3 days prior 
to hospitalization. Further questioning established that she 
had mild generalized abdominal pain and one episode of 
non-bloody diarrhea. The family also noted that she had 
been intermittently confused and was talking gibberish. 
On the morning of admission, she had severe chest pain 
associated with nausea, vomiting and dyspnea on exertion, 
which led her to seek medical care. Her medical history was 
notable for a transient ischemic attack 7 years prior. An 
extensive thrombophilia work-up at that time was negative. 
She also had a history of two miscarriages in the past.
On examination, she appeared toxic and in respiratory 
distress. Vital signs revealed a blood pressure of 
126/70 mmHg with a heart rate of 121 beats per minute. 
Her temperature at admission was 34.4°C. The respiratory 
rate was 30 breaths per minute. Oxygen saturation was 
100% on a non-re-breather mask. She was pale, cold and 
clammy with delayed capillary refill. She had cyanosis in 
all fingers with mild cyanosis of her tongue and lips. In 
addition, mottling of her skin and livedo reticularis over the 
thighs was noted. There were a few purpuric skin lesions 
observed in her antecubital fossa and upper arms. Her 
jugular venous pressure was elevated up to the angle of 
the jaw. Cardiac exam revealed a normal first and second 
heart sound along with a fourth heart sound. There were 
no murmurs. Peripheral pulses were not palpable in the feet 
and were only faintly palpable in the arms. The lungs were 
clear to auscultation. Abdominal exam was unremarkable. 
There was no peripheral edema. Neurologically, she was 
somewhat confused, but the sensory and motor exam was 
essentially normal. Given that the patient was not having 
active chest pain, the history was inconsistent with ACS 
and she appeared more toxic than expected for a lateral wall 
myocardial infarction; cardiac catheterization was deferred 
and emergent laboratory studies were obtained.
Initial laboratory studies revealed a white blood cell count 
of 13.5 × 103/mm3; hematocrit of 24%; mean corpuscular 
volume of 88.4 fL and platelet count of 6 × 109/L. Her lactate 
dehydrogenase was elevated at 2820 units/L and haptoglobin 
was low at less than 10 mg/dL. Coagulation profile showed 
international normalized ratio of 1.2, prothrombin time 
of 12.6 seconds, fibrinogen 199 mg/  L and D-dimer 1.27 
feu mg/L. Electrolytes were within normal limits; acute 
kidney injury was noted with blood urea nitrogen 51 mg/  dL 
and creatinine 1.9 mg/dL. Total bilirubin was markedly 
elevated at 32 mg% with an indirect bilirubin of 2.1 mg%. 
Cardiac biomarkers were elevated with creatinine kinase of 
487 units/L and MB fraction of 28.8 ng/mL. Troponin-T 
was 0.86 ng/mL. Urinalysis showed pH of 6.0, 3+ albumin, 
3+ hemoglobin, eight WBCs and greater than two RBCs with 
some amorphous crystals. Peripheral smear showed moderate 
schistocytes, few spherocytes and low platelet count. Chest 
radiograph showed no cardiopulmonary abnormalities. 
Echocardiography demonstrated an ejection fraction of 
40–45% with severe hypokinesis of the inferior and basal 
anteroseptal wall. No significant valvular lesions were noted.
In view of the acute onset of symptoms associated with 
microangiopathic hemolytic anemia, thrombocytopenia, 
acute kidney injury and waxing and waning mental 
status, the presumptive diagnosis of TTP was made. 
Further coagulopathy testing was negative. A Disintegrin 
and Metalloproteinase with Thrombospondin Motifs 
(ADAMST-13) activity was found to be low with presence 
of ADAMST-13 inhibitors in the plasma.
Plasmapheresis was started immediately. Intravenous 
steroid therapy was also initiated. She improved clinically 
with this treatment and normalized her platelets and lactate 
dehydrogenase, and STE in her ECG resolved [Figure 2]. 
Figure 2: Sinus tachycardia at 113 beats per minute with resolved 
ST-segment changes
Figure 1: Sinus tachycardia at 121 beats per minute with ST segment 
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She was discharged home after a full recovery. Outpatient 
cardiovascular follow-up demonstrated normalization of 
the left ventricular ejection fraction by echocardiography 
and a completely normal nuclear myocardial perfusion 
stress study. Further testing with invasive catheterization 
was not pursued as the entire episode was considered to 
be transient, secondary to metabolic derangement.
DISCUSSION
TTP is defined as a severe, thrombotic microangiopathy 
that is characterized primarily by systemic platelet-von 
Willebrand factor aggregation, organ ischemia, profound 
thrombocytopenia and fragmentation of erythrocytes.[2] 
Intravascular coagulation is not considered a prominent 
feature of the disorder. Clinically, widespread organ 
dysfunction is usually present. Pathologically, focal 
areas of necrosis and hemorrhage may be seen in the 
pancreas, adrenals, heart, brain and kidneys.[3-5] Although 
myocardial injury and necrosis are observed in a large 
number of patients with TTP, it is infrequently the initial 
presentation,[6] and most likely thought to be due to 
microthrombi from massive platelet aggregation than 
plaque rupture–thrombosis cascade.[7] Various studies have 
determined the incidence of myocardial infarction in TTP 
to range from 15–41%.[6-9] However, the heart is one of the 
most frequently involved organs at autopsy examination of 
patients with TTP.[3,10,11] Mortality is considerably higher in 
patients with TTP who have positive cardiac biomarkers, 
necessitating closer monitoring in this subgroup.[7,9,12]
Early recognition of myocardial injury in a case of TTP 
is crucial as it identifies higher risk. However, invasive 
therapy in the form of cardiac catheterization and PCI may 
be fraught with complications and is precluded by acute 
kidney injury and low platelet count.[8] Thrombocytopenia 
also prevents the use of usual medical management in 
ACS such as antiplatelet and anticoagulant therapy.[9] 
Angiotensin converting enzyme inhibitors are also not 
used because of concomitant renal injury. Beta blockers 
and HMG CoA reductase inhibitors may be used although 
their role is questionable.[9] In acute bouts of TTP, such 
as this case, the treatment of choice is rapid initiation of 
plasmapheresis. In addition, immunosuppressive therapy 
including steroid therapy is helpful, especially in the 
setting of auto-antibodies against ADAMST-13 factor.[13,14] 
Relapsing cases of TTP have been treated with rituximab, 
a monoclonal antibody against CD20 on memory B cells 
with good effect. However, large clinical trials are lacking 
for this.[13]
In conclusion, STE myocardial infarction is a very 
common presentation in the emergency rooms. A rapid 
evaluation is needed to identify infrequent causes of STE 
myocardial infarction. Although cardiac involvement is 
common in TTP, as an index event it can be misleading. 
As swift protocols are activated in the emergency room 
and catheterization laboratories to ensure quality control, 
it is equally important to integrate all aspects of patient’s 
clinical and objective data to detect unusual disease entities. 
Once identified, a multidisciplinary approach is essential 
for rapid treatment of TTP.
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